P.N. Munster

751 total citations
18 papers, 584 citations indexed

About

P.N. Munster is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, P.N. Munster has authored 18 papers receiving a total of 584 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in P.N. Munster's work include HER2/EGFR in Cancer Research (9 papers), Cancer Treatment and Pharmacology (5 papers) and Advanced Breast Cancer Therapies (4 papers). P.N. Munster is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Cancer Treatment and Pharmacology (5 papers) and Advanced Breast Cancer Therapies (4 papers). P.N. Munster collaborates with scholars based in United States, France and Spain. P.N. Munster's co-authors include Ann M. Kapoun, Akash Patnaik, Patricia LoRusso, Lu Xu, Charles Zacharchuk, Gail Eckhardt, Renata Ferrarotto, John V. Heymach, Mario Campone and David Lee and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

P.N. Munster

18 papers receiving 576 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P.N. Munster United States 12 336 307 119 79 72 18 584
Davide Torti Italy 12 304 0.9× 418 1.4× 116 1.0× 137 1.7× 77 1.1× 17 677
Oriol Arpí Spain 15 376 1.1× 359 1.2× 126 1.1× 149 1.9× 61 0.8× 24 710
B. Markman Australia 8 293 0.9× 469 1.5× 152 1.3× 69 0.9× 88 1.2× 20 688
Nerissa Mendoza United States 8 229 0.7× 335 1.1× 245 2.1× 98 1.2× 95 1.3× 10 620
Haby Henary United States 14 378 1.1× 376 1.2× 199 1.7× 117 1.5× 68 0.9× 32 702
Raul Ayala United States 9 356 1.1× 483 1.6× 253 2.1× 124 1.6× 69 1.0× 18 830
Astrid Koehler Switzerland 10 330 1.0× 316 1.0× 69 0.6× 166 2.1× 75 1.0× 15 577
J. Baselga Spain 10 399 1.2× 312 1.0× 139 1.2× 188 2.4× 44 0.6× 25 649
Brett H. Simmons United States 8 201 0.6× 257 0.8× 151 1.3× 124 1.6× 59 0.8× 9 488
Dan Lu China 9 203 0.6× 458 1.5× 85 0.7× 131 1.7× 48 0.7× 16 694

Countries citing papers authored by P.N. Munster

Since Specialization
Citations

This map shows the geographic impact of P.N. Munster's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P.N. Munster with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P.N. Munster more than expected).

Fields of papers citing papers by P.N. Munster

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P.N. Munster. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P.N. Munster. The network helps show where P.N. Munster may publish in the future.

Co-authorship network of co-authors of P.N. Munster

This figure shows the co-authorship network connecting the top 25 collaborators of P.N. Munster. A scholar is included among the top collaborators of P.N. Munster based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P.N. Munster. P.N. Munster is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Wolin, Edward M., Alain C. Mita, Amit Mahipal, et al.. (2019). A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. PLoS ONE. 14(9). e0221994–e0221994. 26 indexed citations
2.
3.
Ferrarotto, Renata, Gail Eckhardt, Akash Patnaik, et al.. (2018). A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Annals of Oncology. 29(7). 1561–1568. 101 indexed citations
4.
DeMichele, A., P.N. Munster, Othon Iliopoulos, et al.. (2017). Abstract P6-11-05: Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), in combination with paclitaxel (Pac) in patients (its) with triple negative breast cancer (TNBC). Cancer Research. 77(4_Supplement). P6–11. 1 indexed citations
5.
Juric, Dejan, Roohi Ismail‐Khan, Mario Campone, et al.. (2016). Abstract P3-14-01: Phase Ib/II study of ribociclib and alpelisib and letrozole in ER+, HER2– breast cancer: Safety, preliminary efficacy and molecular analysis. Cancer Research. 76(4_Supplement). P3–14. 30 indexed citations
6.
Hochster, H. S., John H. Strickler, Ann M. Kapoun, et al.. (2016). Initial results from a phase 1a/b study of OMP-131R10, a first-in-class anti-RSPO3 antibody, in advanced solid tumors and previously treated metastatic colorectal cancer (CRC). European Journal of Cancer. 69. S29–S30. 21 indexed citations
7.
8.
Piha‐Paul, Sarina A., P.N. Munster, Antoine Hollebecque, et al.. (2015). Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours. European Journal of Cancer. 51(14). 1865–1873. 63 indexed citations
9.
Kelley, Robin Kate, Halla Nimeiri, P.N. Munster, et al.. (2013). Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Annals of Oncology. 24(7). 1900–1907. 50 indexed citations
10.
11.
Campone, Mario, Igor Bondarenko, Stephen Brincat, et al.. (2011). Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Annals of Oncology. 23(3). 610–617. 77 indexed citations
12.
13.
Sparano, Joseph A., Stacy L. Moulder, Aslamuzzaman Kazi, et al.. (2009). Phase II Trial of Tipifarnib plus Neoadjuvant Doxorubicin-Cyclophosphamide in Patients with Clinical Stage IIB-IIIC Breast Cancer. Clinical Cancer Research. 15(8). 2942–2948. 55 indexed citations
14.
Rugo, Hope S., Sandra Franco, P.N. Munster, et al.. (2008). A phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2+ metastatic breast cancer (MBC). Journal of Clinical Oncology. 26(15_suppl). 1042–1042. 16 indexed citations
15.
Munster, P.N., et al.. (2008). Akute Chloroquin-Intoxikation. DMW - Deutsche Medizinische Wochenschrift. 122(8). 225–228. 2 indexed citations
16.
Ismail‐Khan, Roohi, S. Minton, Catrin Cox, et al.. (2008). Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer: A randomized trial using the GnRH agonist (triptorelin) during chemotherapy. Journal of Clinical Oncology. 26(15_suppl). 524–524. 28 indexed citations
17.
Sparano, Joseph A., Stacy L. Moulder, Aslamuzzaman Kazi, et al.. (2006). Targeted Inhibition of Farnesyltransferase in Locally Advanced Breast Cancer: A Phase I and II Trial of Tipifarnib Plus Dose-Dense Doxorubicin and Cyclophosphamide. Journal of Clinical Oncology. 24(19). 3013–3018. 54 indexed citations
18.
Wong, Kwok‐Kin, Paula M. Fracasso, Ronald M. Bukowski, et al.. (2006). HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: Preliminary phase 1 results in patients with solid tumors. Journal of Clinical Oncology. 24(18_suppl). 3018–3018. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Davide Torti Breakdown of academic impact, for papers by Oriol Arpí Breakdown of academic impact, for papers by B. Markman Breakdown of academic impact, for papers by Nerissa Mendoza Breakdown of academic impact, for papers by Haby Henary Breakdown of academic impact, for papers by Raul Ayala Breakdown of academic impact, for papers by Astrid Koehler Breakdown of academic impact, for papers by J. Baselga Breakdown of academic impact, for papers by Brett H. Simmons Breakdown of academic impact, for papers by Dan Lu
Rankless by CCL
2026